Polypide

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

Retrieved on: 
Monday, May 23, 2022
SHIELD, QIDP, Company, Hospital, Private Securities Litigation Reform Act, SOC, Polypide, Infection, PLEX, Patient, Nature, Mortality, Regulation of pesticides in the European Union, SSIS, FDA, Partnership, Forward-looking statement, Safety, Technology, Glioblastoma, Standard of care, NDA, LinkedIn, Breakthrough therapy, Twitter, Colorectal surgery, Arm, Surgery, Active ingredient, Pharmaceutical industry

PETACH TIKVA, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that following the independent Data Safety Monitoring Board (DSMB) review of unblinded efficacy data from the first 750 enrolled patients in the SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal tissue surgery, the recommendation was to conclude the study upon enrollment of 950 patients, which is the minimum number of targeted patients in the study protocol. The enrollment of the 950th patient is expected to occur within days.

Key Points: 
  • The trial has enrolled patients in more than 60 centers inthe United States,EuropeandIsrael.
  • D-PLEX100, PolyPids lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
  • D-PLEX100 received Breakthrough Therapy Designation from the U.S. FDA for the prevention of SSIs in patients undergoing elective colorectal surgery.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws.

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022
SHIELD, Surgery, Polypide, Teva Pharmaceuticals, GLOBE, Development, Company, Regulatory affairs, Research, Infection, Patient, SSIS, Hospital, Leadership, Marketing, R, PLEX, Conference, G&A, Research and development, KREO, Financial result, Online gambling, Medicine, Pharmaceutical industry, Operation

PETACH TIKVA,Israel, May 11, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd.(Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2022.

Key Points: 
  • PETACH TIKVA,Israel, May 11, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd.(Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2022.
  • Recruitment progressing as planned with approximately 900 patients enrolled into the ongoing Phase 3 SHIELD I study.
  • The first $10 million of the facility was drawn in April 2022.
  • PolyPid expects that its cash balance, together with the first tranche of $10 million from the Kreos loan that was drawn in April 2022, will be sufficient to fund operations into the second quarter of 2023.

PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

Retrieved on: 
Wednesday, April 27, 2022
LinkedIn, Polypide, PLEX, API, Technology, Infection, Company, Active ingredient, Glioblastoma, Twitter, Pharmaceutical industry, Online shopping

PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes.

Key Points: 
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections.
  • In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.
  • For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn .

PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

Retrieved on: 
Monday, April 25, 2022
Patient, Polypide, Colorectal surgery, Twitter, Randomness, Incidence, Infection, Active ingredient, GLOBE, Glioblastoma, LinkedIn, Technology, Company, PLEX, Medical device, Pharmaceutical industry, Nanomedicine

PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022. The focus of this year’s summit is From Hope to Product – The Brilliant Prospect in Nanomedicine and Related Fields.

Key Points: 
  • PETACH TIKVA, Israel, April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine , being held virtually on May 24, 2022.
  • The focus of this years summit is From Hope to Product The Brilliant Prospect in Nanomedicine and Related Fields.
  • Dr. Emanuels presentation will be available on https://www.polypid.com/ following the summit.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes.

PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Polypide, SSIS, Annual general meeting, Twitter, Infection, Active ingredient, GLOBE, Glioblastoma, Patient, SIS, LinkedIn, Technology, Company, PLEX, Colorectal surgery, Pharmaceutical industry

PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting , being held on April 23-26, 2022 in Dallas, TX.

Key Points: 
  • PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting , being held on April 23-26, 2022 in Dallas, TX.
  • The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the presentation.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections.

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

Retrieved on: 
Wednesday, April 6, 2022
SHIELD, Company, Private Securities Litigation Reform Act, PLEX, LinkedIn, Glioblastoma, Investment, API, Forward-looking statement, Health care, QIDP, SSIS, U.S. Securities and Exchange Commission, Food, Colorectal surgery, Barcode technology in healthcare, Active ingredient, Polypide, Technology, Twitter, Intellectual property, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Infection, Sonia, Nature, FDA, 750th Bombardment Squadron, Patient, Security (finance), Pharmaceutical industry, KREO (FM)

The loan facility is comprised of three tranches in the amount of $10.0 million, $2.5 million, and $2.5 million, respectively, with a drawdown of the first tranche available upon the execution of the agreement.

Key Points: 
  • The loan facility is comprised of three tranches in the amount of $10.0 million, $2.5 million, and $2.5 million, respectively, with a drawdown of the first tranche available upon the execution of the agreement.
  • The senior secured loan initially bears interest at a rate of 9.25%, which may be reduced to 8.75% upon reaching certain milestones.
  • The loan is prepayable in full, at any time at the option of PolyPid.
  • The loan is secured by PolyPid's owned equipment and intellectual property, and the Company will pay a customary fee to Kreos for the establishment of the loan.

PolyPid to Deliver Poster Presentation at SAGES 2022

Retrieved on: 
Tuesday, March 8, 2022
PLEX, Society, Infection, Twitter, LinkedIn, Doxycycline, Company, Colorectal surgery, Active ingredient, Annual general meeting, Polypide, Glioblastoma, API, Technology, GLOBE, Pharmaceutical industry

PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes announced it will be presenting clinical data at the upcoming SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) 2022 Annual Meeting, being held on March 16-19, 2022 in Denver, Colorado.

Key Points: 
  • PETACH TIKVA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes announced it will be presenting clinical data at the upcoming SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) 2022 Annual Meeting , being held on March 16-19, 2022 in Denver, Colorado.
  • The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the delivery of the presentation.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes.
  • PolyPid is not responsible for the contents of third-party websites.

PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

Retrieved on: 
Wednesday, March 2, 2022
SHIELD, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Omicron, PLEX, Patient, Hospital, Infection, Forward-looking statement, Twitter, Food, Security (finance), U.S. Securities and Exchange Commission, LinkedIn, Particle-size distribution, QIDP, FDA, SSIS, Company, COVID-19, Polypide, Colorectal surgery, Nature, Technology, GLOBE, Therapy, Pharmaceutical industry

The planned, unblinded interim analysis will strengthen the adaptive design of the study so that we can more precisely define the targeted patient enrollment range.

Key Points: 
  • The planned, unblinded interim analysis will strengthen the adaptive design of the study so that we can more precisely define the targeted patient enrollment range.
  • It can also potentially allow for stopping the trial earlier than planned, if the efficacy results on SSIs are overwhelming.
  • PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).

PolyPid to Present at the Barclays Global Healthcare Conference

Retrieved on: 
Tuesday, March 1, 2022
Technology, Polypide, LinkedIn, Barclays, Twitter, SSIS, PLEX, Pharmaceutical industry

Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

Key Points: 
  • Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.
  • PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).
  • PolyPid is not responsible for the contents of third-party websites.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Wednesday, February 9, 2022
SHIELD, Board of directors, GLOBE, NDA, SSIS, Regulation of tobacco by the U.S. Food and Drug Administration, G&A, Conference, Infection, Company, Polypide, Financial result, PLEX, FDA, Patient, Surgery, First, Particle-size distribution, Hospital, End, Therapy, Research, History, Insurance, Food, R, Marketing, COVID-19, Medical imaging, Pharmaceutical industry, Cryptocurrency, Animal, Ridesharing company

PETACH TIKVA, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today provided a corporate update and reported financial results for the three months and full-year ended December 31, 2021.

Key Points: 
  • Recruitment progressing as planned with approximately 680 patients enrolled into the ongoing Phase 3 SHIELD I study.
  • It can also potentially allow for stopping the trial earlier than planned, if the efficacy results on SSIs are above expectations.
  • We believe PolyPid is in the strongest operational position in its history, and we are well-positioned for long-term success.
  • PolyPid expects that this cash balance will be sufficient to fund operations through the end of 2022.